Mono drug group of Rosuvastatin
ApprovedSmall molecule
Mono drug group of Rosuvastatin is one of 40 small molecule programs targeting Coronary Artery Disease. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
223 competitors in Coronary Artery Disease
#DrugCompanyPhaseTrials
1Colcrys
Alnylam PharmaceuticalsPhase 3
Leqvio
NovartisPhase 3
Byetta
AstraZenecaPhase 3
Zetia
OOrganon and Co
Phase 3
Xe-133
NNobilis Therapeutics Inc.
Phase 3
Ridaforolimus
Merck & Co.Phase 3
Glutamine
SanofiPhase 3
Quercetin
MMayo Clinic
Phase 3
Mono drug group of Rosuvastatin
SSaint Vincent's Hospital, Korea
Approved
Praluent
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSaint Vincent's Hospital, Korea